Replies to post #212752 on Biotech Values

[DewDiligence]

REGN’s transgenic-mouse patent invalid due to inequitable conduct, says CAFC:

https://www.pharmapatentsblog.com/2017/08/01/regeneron-patent-inequitable-conduct

[DewDiligence]

REGN/SNY sunset antibody collaboration after 10 years—separate I-O collaboration continues:

https://finance.yahoo.com/news/teva-reports-second-quarter-2017-103000375.html

The Company's Antibody Discovery Agreement with Sanofi will end on December 31, 2017 without any extension. Praluent (anti-PCSK9), Dupixent (anti-IL-4R), Kevzara (anti-IL-6R), REGN2810 (anti-PD-1), REGN3500 (anti-IL-33), and REGN3767 (anti-LAG-3) were discovered and initially developed under the Antibody Discovery Agreement. Praluent, Dupixent, Kevzara, and REGN3500 will continue to be developed, and commercialized as applicable, with Sanofi under the Antibody License and Collaboration Agreement.

REGN2810 and REGN3767 will continue to be developed with Sanofi under the [separate] immuno-oncology collaboration.

The 2017 end to the antibody collaboration was expected, but not formally disclosed until now.

[DewDiligence]

SNY/REGN—PDUFA date for Dupixent BLA in asthma is 10/20/18:

https://globenewswire.com/news-release/2018/03/02/1409600/0/en/Sanofi-FDA-to-review-Dupixent-dupilumab-as-potential-treatment-for-moderate-to-severe-asthma.html